Johnson & Johnson (FRA:JNJ)
Germany · Delayed Price · Currency is EUR | Market Cap | 424.32B |
| Revenue (ttm) | 78.81B |
| Net Income (ttm) | 21.48B |
| Shares Out | n/a |
| EPS (ttm) | 8.85 |
| PE Ratio | 19.75 |
| Forward PE | 18.71 |
| Dividend | 4.57 (2.58%) |
| Ex-Dividend Date | Nov 25, 2025 |
| Volume | 187 |
| Average Volume | 501 |
| Open | 177.00 |
| Previous Close | 179.90 |
| Day's Range | 177.00 - 178.12 |
| 52-Week Range | 129.00 - 183.20 |
| Beta | n/a |
| RSI | 54.50 |
| Earnings Date | Jan 21, 2026 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial numbers in USD Financial StatementsNews
FDA Approves J&J's New 5-Minute Injection For Lung Cancer
On Wednesday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson (NYSE: JNJ) Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), the first and only subcutaneously (SC) administ...
J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant
JNJ wins FDA approval for a subcutaneous version of Rybrevant, cutting treatment time to minutes and boosting convenience across NSCLC indications.
Noteworthy ETF Inflows: IWX, JNJ, BAC, WFC
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell Top 200 Value ETF (Symbol: IWX) where we have detected...
Johnson & Johnson (JNJ) Receives FDA Approval for Expanded Use of TRUFILL System
Johnson & Johnson (JNJ) Receives FDA Approval for Expanded Use of TRUFILL System
Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma
- TRUFILL n-BCA is now indicated for embolization of the middle meningeal artery (MMA) for the treatment of symptomatic subacute and Chronic Subdural Hematoma (cSDH) as an adjunct to surgery. - Approv...
FDA Approves Injectable Rybrevant for JNJ, Offering New NSCLC Treatment Option
FDA Approves Injectable Rybrevant for JNJ, Offering New NSCLC Treatment Option
J&J wins FDA nod for Rybrevant injectable in lung cancer
Johnson & Johnson (JNJ) stock is in focus as the FDA greenlights the company's Rybrevant injectable developed with Halozyme (HALO) for lung cancer. Read more here.
Johnson & Johnson: Valuation Premium Justified By Accelerating Growth And Mix Premiumization
Johnson & Johnson's portfolio reshaping should enhance margins and long-term growth prospects. Click here to read why JNJ stock is a Buy.
FDA Approves Johnson & Johnson's RYBREVANT FASPRO, First Subcutaneous Therapy For EGFR-Mutated NSCLC
(RTTNews) - Johnson & Johnson (JNJ) announced that the U.S. Food and Drug Administration has approved RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj), the first and only subcutaneously (SC) admi...
FDA Greenlights JNJ's Innovative Cancer Treatment: RYBREVANT FASPRO
FDA Greenlights JNJ's Innovative Cancer Treatment: RYBREVANT FASPRO
U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)
RYBREVANT FASPRO™, the first and only subcutaneous therapy for patients with EGFR-mutated NSCLC, reduces administration time from hours to minutes and significantly reduces administration-related reac...
Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Is Monte Rosa Stock Trading Higher Today?
Monte Rosa Therapeutics Inc . (NASDAQ: GLUE) shared interim data from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with meta...
2 Recession-Proof Stocks to Watch in December
Walmart's low prices make it a go-to during recessions when people are cutting back on spending. Johnson & Johnson sells consumer health products that many people don't cut back on when adjusting thei...
Johnson & Johnson: Quality Compounding, Valuations Now Do The Heavy Lifting
Final Trade: JNJ, NVO, UBER, BMY
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Final Trade: JNJ, NVO, UBER, BMY
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, January 21st to review fourth-quarter results. J...
Notable Monday Option Activity: BBY, JNJ, AMC
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Best Buy Inc (Symbol: BBY), where a total of 19,800 contracts have traded so far, represent...
Johnson & Johnson (JNJ) Achieves Priority Voucher for Multiple Myeloma Therapy
Johnson & Johnson (JNJ) Achieves Priority Voucher for Multiple Myeloma Therapy
FDA Approves J&J's Akeega for Expanded Use in Prostate Cancer
JNJ secures FDA approval to expand Akeega into earlier-stage prostate cancer, backed by strong phase III data and a first-of-its-kind precision combo.
US FDA grants priority voucher to J&J's blood cancer treatment
The U.S. Food and Drug Administration said on Monday it has granted a national priority voucher to Johnson & Johnson's treatment for a type of blood cancer, bringing the total number of products recei...
Johnson & Johnson (JNJ) Is Considered a Good Investment by Brokers: Is That True?
Based on the average brokerage recommendation (ABR), Johnson & Johnson (JNJ) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness...
Johnson & Johnson Wins FDA Nod For First Precision Combo For Mutated Prostate Cancer
On Friday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson's (NYSE: JNJ) supplemental New Drug Application (sNDA) for Akeega (niraparib and abiraterone acetate) plus prednisone...
Take the Zacks Approach to Beat the Markets: Liquidia, Western Digital & Johnson & Johnson in Focus
Liquidia shares have surged 43.9% since an October upgrade, as Zacks highlights stock wins and portfolio results despite a volatile market.